Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 12/20 | 0.41 |
| ▸ | DRD2 | P14416 | 12/20 | 0.41 |
| ▸ | DRD4 | P21917 | 5/20 | 0.41 |
| ▸ | HTR1B | P28222 | 3/20 | 0.41 |
| ▸ | HTR1D | P28221 | 3/20 | 0.41 |
| ▸ | HRH2 | P25021 | 2/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL939870 | 0.96 | DRD3 (0.42) | DRD3DRD2DRD4HTR1BHTR1D | |
| SCHEMBL21047707 | 0.84 | GNAI3 (0.46) | DRD3DRD2SIGMAR1 | |
| SCHEMBL11294055 | 0.82 | GNAI3 (0.53) | DRD3DRD2 | |
| SCHEMBL21047738 | 0.81 | GNAI3 (0.56) | DRD3DRD2 | |
| SCHEMBL21047880 | 0.81 | GNAI3 (0.56) | DRD3DRD2 | |
| SCHEMBL21047868 | 0.81 | GNAI3 (0.56) | DRD3DRD2 | |
| SCHEMBL21047754 | 0.81 | GNAI3 (0.56) | DRD3DRD2 | |
| SCHEMBL21047578 | 0.81 | GNAI3 (0.56) | DRD3DRD2 | |
| SCHEMBL11014162 | 0.81 | GNAI3 (0.56) | DRD3DRD2 | |
| SCHEMBL11004775 | 0.81 | GNAI3 (0.56) | DRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1884514-B1 | METHOD FOR THE RESOLUTION OF 2-AMINO-6-PROPYLAMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOL AND INTERMEDIATE COMPOUNDS | CRYSTAL PHARMA SAU (ES) | 2017-04-12 | — | — | EP | disclosed |
| US-8952173-B2 | Method for the resolution of 2-amino-6-propylamino-4,5,6,7-tetrahydrobenzothiazol and intermediate compounds | CRYSTAL PHARMA, S.A.U. (ES) | 2015-02-10 | — | — | US | disclosed |
| US-7875750-B2 | amination, reacting enamine with sulfur in presence of solvent, reacting with cyanamide; for production of Pramipexole, dopamine D-2 agonist; for treatment of Parkinson's disease and schizophrenia | RAGACTIVES, S.L. (ES) | 2011-01-25 | — | — | US | disclosed |
| US-20100063324-A1 | METHOD OF OBTAINING 2-AMINO-6-ALKYL-AMINO-4,5,6,7- TETRAHYDROBENZOTHIAZOLES | RAGACTIVES, S.L. (ES) | 2010-03-11 | — | — | US | disclosed |
| US-7638542-B2 | Method of obtaining 2-amino-6-alkyl-amino-4,5,6,7-tetrahydro-benzothiazoles | RAGACTIVES, S.L. (ES) | 2009-12-29 | — | — | US | disclosed |
| EP-1783120-B1 | METHOD OF OBTAINING 2-AMINO-6-ALKYL-AMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOLES | RAGACTIVES SL (ES) | 2009-05-06 | — | — | EP | disclosed |
| US-20080194832-A1 | S-enantiomer is pramipexole; reaction with an optically pure chiral di-p-toluyl tartaric acid to form the acid salt; crystallization | RAGACTIVES, S.L. (ES) | 2008-08-14 | — | — | US | disclosed |
| EP-1884514-A1 | METHOD FOR THE RESOLUTION OF 2-AMINO-6-PROPYLAMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOL AND INTERMEDIATE COMPOUNDS | Ragactives, S.L. (ES) | 2008-02-06 | — | — | EP | disclosed |
| US-20070161798-A1 | Method of obtaining 2-amino-6-alkyl-amino-4,5,6,7- tetrahydro-benzothiazoles | CRYSTAL PHARMA, S.A.U. (ES) | 2007-07-12 | — | — | US | disclosed |
| EP-1783120-A1 | METHOD OF OBTAINING 2-AMINO-6-ALKYL-AMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOLES | Ragactives, S.L. (ES) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194832-A1 | S-enantiomer is pramipexole; reaction with an optically pure chiral di-p-toluyl tartaric acid to form the acid salt; crystallization | DNPEP, DPP4, SRR | DRD3 775/4885DRD2 743/4885DRD4 166/4885 |
| US-20100063324-A1 | METHOD OF OBTAINING 2-AMINO-6-ALKYL-AMINO-4,5,6,7- TETRAHYDROBENZOTHIAZOLES | SNCA, CHRM2, PARK7 | DRD3 63/4885DRD2 9/4885DRD4 8/4885 |
| US-20070161798-A1 | Method of obtaining 2-amino-6-alkyl-amino-4,5,6,7- tetrahydro-benzothiazoles | SNCA, PARK7, CHRM2 | DRD3 80/4885DRD2 13/4885DRD4 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.